Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Vikram Soman"'
Autor:
Xuqing Zhang, Mengyao Luo, Shamael R. Dastagir, Mellissa Nixon, Annie Khamhoung, Andrea Schmidt, Albert Lee, Naren Subbiah, Douglas C. McLaughlin, Christopher L. Moore, Mary Gribble, Nicholas Bayhi, Viral Amin, Ryan Pepi, Sneha Pawar, Timothy J. Lyford, Vikram Soman, Jennifer Mellen, Christopher L. Carpenter, Laurence A. Turka, Thomas J. Wickham, Tiffany F. Chen
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Red blood cells (RBCs) have unique properties that have been exploited for therapeutic uses. Here the authors engineer RBCs to co-express tumor associated antigens on MHC I, 4-1BBL and IL-12, generating artificial antigen presenting cells that can in
Externí odkaz:
https://doaj.org/article/81c7237bdaba401f8b24431f73e5d95a
Autor:
Douglas C. McLaughlin, Naren Subbiah, Timothy J. Lyford, Laurence A. Turka, Xuqing Zhang, Nicholas Bayhi, Shamael R. Dastagir, Mary Gribble, Ryan Pepi, Mengyao Luo, Viral Amin, Tiffany F. Chen, Christopher L. Moore, Annie Khamhoung, Christopher L. Carpenter, Mellissa J. Nixon, Albert Lee, Vikram Soman, Andrea Schmidt, Jennifer Mellen, Sneha Pawar, Thomas Joseph Wickham
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Checkpoint inhibitors and T-cell therapies have highlighted the critical role of T cells in anti-cancer immunity. However, limitations associated with these treatments drive the need for alternative approaches. Here, we engineer red blood cells into
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af31c099b49bd4a4f5ad78430492c949
https://doi.org/10.1038/s41467-021-22898-3
https://doi.org/10.1038/s41467-021-22898-3
Autor:
Tiffany F. Chen, Shamael R. Dastagir, Naren Subbiah, Xuqing Zhang, Mengyao Luo, Christopher L. Carpenter, Nicholas Bayhi, Torben Straight Nissen, Vikram Soman, Sneha Pawar, Douglas C. McLaughlin, Viral Amin, Thomas Wickham
Publikováno v:
Cancer Research. 79:3260-3260
T cell-based therapies have demonstrated efficacy in a small subset of cancers; however, they have the potential to proliferate uncontrollably and manufacturing these therapies at scale has proven difficult. To address this limitation, Rubius Therape
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::533c48c7b4d8bcca5ed46b1b87b6ff0d
https://doi.org/10.1158/1538-7445.am2019-3260
https://doi.org/10.1158/1538-7445.am2019-3260